About Pyxis Diagnostics
basic-triangle-bottom.png

About Pyxis Diagnostics

The human immune system can efficiently eradicate even widespread metastatic tumors, delivering durable survival benefit to cancer patients. Unfortunately, only a small subset of cancer patients benefit from immunotherapy; the rest lose valuable time and may suffer from diverse adverse events. Hence, biomarkers that predict a patient’s response to immunotherapy are in urgent need.

Immune Related Parameters

Immune Related Parameters

Over the years, several parameters were found to correlate with response to immunotherapy. The most prominent immune-related parameters are:​

  1. The various immune subsets’ relative abundance within the tumor

  2. The expression and co-expression patterns of different Immune Check Point (ICP)-related molecules on each cell-subset

  3. The immune state of each subset (e.g., activated, exhausted, its cytokine-polarization, metabolic state etc.)

Our Diagnostic Platform

Our Diagnostic Platform

Our diagnostic platform integrates all prominent immune parameters defined above and more, generating unique delineation of the tumor - immune - stroma microenvironment formed within human tumors.

This approach may provide better understanding on the structure and function of the inter-cellular communication network (ICCN) that protect tumor tissue from immune-mediated assault

network2-05.png

Pyxis Mission

PyxisDX Develops a diagnostics platform for predicting IO drug response, and for the discovery of new drug combinations, by mapping the tumor-immune communication network.

Leading Team

Dr. Yosef Reut, Ph.D.
weizmann.png

Dr. Yosef Reut, Ph.D.
CTO

Vast industrial experience in multidisciplinary research and development of novel drugs in immuno-oncology, autoimmunity, ageing and development of computational platforms for precision medicine.

yael.jpg
tau copy.jpg

Yael Silberberg, Ph.D.
VP, Data Sciences

Ms. Silberberg has 25 years of experience in the field of computer science and been focusing on Computational Biology for the past 15 years. Holds a PhD in bioinformatics from the University of Tel Aviv and has vast experience in the industry both as a engineer, researcher and manager.

Dr. Aviv De-Morgan, Ph.D.
weizmann.png

Dr. Aviv De-Morgan, Ph.D.
Head of Bioinformatics

Expert in bioinformatic analysis of NGS data: DNA, RNA and other, NGS automation, highly experienced in statistical modelling of cancer evolution.

Dr. Ravit Geva, M.D
sorasky.png

Dr. Ravit Geva, M.D
Chief Medical Officer (CMO)

Head of the GIT malignancies center. Head of the oncology clinical research & Innovation unit Deputy director of the oncology division at the medical center in Tel Aviv Sourasky Medical Center, Israel

Dr. Bar Nathansohn, Ph.D.
weizmann.png

Dr. Bar Nathansohn, Ph.D.
Head of biological team

Broad background in immune-oncology, immune tolerance mechanism and cell therapy. Skills in Flow Cytometry, CyTOF, animal models and molecular biology.

Dr. Ilan Volovitz, Ph.D.
weizmann.png
sorasky.png

Dr. Ilan Volovitz, Ph.D.
CSO

Head of Cancer Immunotherapy lab, the Neurosurgery department, The Tel-Aviv Sourasky Medical Center

irit.jpg
sorasky.png

Dr. Irit Solar, Ph.D., MHA
Head of Clinical Operations

Vast experience in Molecular Pathology: Implementation, validation, analysis and reporting cutting edge clinical molecular pathology testing for diagnosis and personalized medicine. Broad experience in clinical laboratory management.

Avia Zisso, M.Sc.
weizmann.png

Avia Zisso, M.Sc.
NGS lab manager

Highly experienced in NGS, DNA and RNA library preparation, analysis and decoding of DNA sequences for clinical diagnosis, and use of bioinformatics tool for analysis.

Board

ori.jpg

Ori Choshen
Chairman of the Board

Ori is the CEO of VLX Ventures, which invests and creates new startups in the biotech and computational biology domains.

Ori  brings with him extensive, multidisciplinary experience in building innovation platforms and establishing, investing in and mentoring innovative startups in the life sciences, pharma, AI, and hi-tech industries.

Anat Cohen-Dayag, Ph.D Board,  President and CEO of Compugen

Anat Cohen-Dayag, Ph.D
Board, President and CEO of Compugen

Dr. Anat Cohen-Dayag has over 25 years of experience in the biotech industry, both in R&D and executive leadership roles. Under her leadership, Compugen transformed from a service provider in the field of computational biology to a therapeutic discovery and development company advancing an innovative immuno-oncology pipeline originating from the company’s computational discovery platforms

Scientific Advisory Board

Prof. Igor Ulitsky, Associate Professor at Weizmann Institute of Science, Advisory

Prof. Igor Ulitsky, Associate Professor at Weizmann Institute of Science, Advisory

Dr. Igor Ulitsky studies the biology of long non-coding RNA (lncRNA) and their functions in regulatory networks controlling gene expression.

Igor is an expert in RNA-sequencing data analysis.

raanan.jpg

Raanan Berger, M.D, Ph.D
Clinical Advisor

Prof. Raanan Berger is a senior oncologist and radiotherapist, serving as Director of the Cancer Center at the Sheba Medical Center, Israel. In 2006, he established the Riva Koschitzky Oncology Clinical Research Unit at Sheba, the largest center for all-phase oncology clinical trials in Israel, currently conducting over 200 advanced clinical trials. In addition, he is a senior lecturer at the Sackler Medical School at the Tel Aviv University, and runs a basic and translational research lab studying molecular mechanisms in prostate and breast tumorigenesis. Prof. Berger is a member of the European Society of Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO), and co-author of over 70 peer reviewed scientific articles. He received his MD and PhD from the Sackler Faculty of Medicine at the Tel Aviv University, Israel, and was a post-doctoral fellow at Dana Farber Cancer Institute, Harvard Medical School.

Collaborations

Kaplan Medical Center
Shamir Medical Center
Tel Aviv Sourasky Medical Center
Rabin Medical Center